<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416272</url>
  </required_header>
  <id_info>
    <org_study_id>ROC2-11-024</org_study_id>
    <nct_id>NCT01416272</nct_id>
  </id_info>
  <brief_title>Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses</brief_title>
  <official_title>Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this twelve month dispensing study is to evaluate the clinical performance,
      particularly comfort and vision, of KeraSoft IC Soft Contact Lenses.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to a business decision to cancel the entire project.
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort</measure>
    <time_frame>4 visits over 1 year</time_frame>
    <description>Symptoms and complaints measured on an analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity - Low Contrast</measure>
    <time_frame>4 visits over 1 year</time_frame>
    <description>Low contrast visual acuity measured with high ambient illumination (LCHI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity - High Contrast</measure>
    <time_frame>4 visits over 1 year</time_frame>
    <description>High contrast visual acuity measured with high ambient illumination (HCHI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>KeraSoft IC Soft Contact Lenses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KeraSoft IC Soft Contact Lenses</intervention_name>
    <description>Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
    <arm_group_label>KeraSoft IC Soft Contact Lenses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have participated and completed a previous study (ROC2-10-078).

          -  Is Keratoconic

        Exclusion Criteria:

          -  Has any systemic disease affecting ocular health.

          -  Is using any systemic or topical medications that will, in the Investigator's opinion,
             affect ocular physiology or lens performance.

          -  Is not correctable to 20/50 or better in each eye with contact lenses.

          -  Has greater than Grade 2 slit lamp exam findings.

          -  Has any atypical scar for a keratoconic or neovascularization within the central 4mm
             of the cornea. Subjects with minor peripheral corneal scarring that, in the
             Investigator's judgment, does not interfere with contact lens wear are eligible for
             this study.

          -  Has any neovascularization within the central 4mm of the cornea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Steffen, OD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <results_first_submitted>November 18, 2014</results_first_submitted>
  <results_first_submitted_qc>November 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2014</results_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KeraSoft IC Soft Contact Lenses</title>
          <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unacceptable distance visual acuity</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study related complaints</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KeraSoft IC Soft Contact Lenses</title>
          <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="33" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comfort</title>
        <description>Symptoms and complaints measured on an analog scale</description>
        <time_frame>4 visits over 1 year</time_frame>
        <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
        <group_list>
          <group group_id="O1">
            <title>KeraSoft IC Soft Contact Lenses</title>
            <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort</title>
          <description>Symptoms and complaints measured on an analog scale</description>
          <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity - Low Contrast</title>
        <description>Low contrast visual acuity measured with high ambient illumination (LCHI)</description>
        <time_frame>4 visits over 1 year</time_frame>
        <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
        <group_list>
          <group group_id="O1">
            <title>KeraSoft IC Soft Contact Lenses</title>
            <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity - Low Contrast</title>
          <description>Low contrast visual acuity measured with high ambient illumination (LCHI)</description>
          <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity - High Contrast</title>
        <description>High contrast visual acuity measured with high ambient illumination (HCHI)</description>
        <time_frame>4 visits over 1 year</time_frame>
        <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
        <group_list>
          <group group_id="O1">
            <title>KeraSoft IC Soft Contact Lenses</title>
            <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity - High Contrast</title>
          <description>High contrast visual acuity measured with high ambient illumination (HCHI)</description>
          <population>DUE TO THE CANCELLATION OF THIS PROJECT, NO STATISTICAL OR CLINICALLY MEANINGFUL CONCLUSIONS RELATED TO THE STUDY ENDPOINTS WERE MADE.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>KeraSoft IC Soft Contact Lenses</title>
          <description>KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
KeraSoft IC Soft Contact Lenses: Lenses will be worn between 8 and 16 hrs each day, for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Steffen, OD, MS</name_or_title>
      <organization>Bausch &amp; Lomb / Valeant Pharmaceuticals</organization>
      <phone>585-338-6399</phone>
      <email>robert.steffen@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

